SPECTRUM PHARMACEUTICALS INC
DelistedCIK 831547fmd_1S42HHC2RSD28S9JKV5KYYR93SManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2009 to Mar 31, 2023, 53 periods
| Line item | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 143 | 187 | 163 | 146 | 0 | 0 | 0 | 0 | 0 | 10 |
| Cost of revenue | – | 0 | 0 | 8 | 4 | – | – | – | – | – |
| Net interest income | (2) | (9) | (9) | (9) | (7) | (0) | 5 | 1 | 0 | 1 |
| Gross profit | – | 187 | 163 | 139 | (4) | – | – | – | – | – |
| Research and development | 47 | 70 | 51 | 59 | 52 | 75 | 79 | 109 | 87 | 42 |
| Selling, general and administrative | 99 | 97 | 88 | 88 | 65 | 63 | 61 | 60 | 60 | 39 |
| Operating income | (39) | (32) | (43) | (63) | (116) | (138) | (141) | (170) | (148) | (73) |
| Interest expense | 0 | 9 | 9 | 10 | 8 | 3 | – | – | – | – |
| Other non-operating income (expense) | 2 | (12) | (10) | (9) | (6) | 9 | (4) | (2) | (11) | (5) |
| Income before taxes | (37) | (44) | (52) | (72) | (123) | (129) | (145) | (171) | (158) | (78) |
| Income tax expense | 25 | 2 | 0 | (2) | (22) | (2) | (9) | (0) | 0 | 0 |
| Net income from continuing operations | (62) | (46) | (53) | (70) | (101) | (127) | (135) | (171) | (158) | (78) |
| Net income | (62) | (46) | (53) | (70) | (92) | (121) | (113) | (161) | (159) | (75) |
| Net income to common shareholders | – | – | – | – | – | – | – | – | – | – |